医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Stemgent, a ReproCELL Group Company Launches a New High Performance Self-replicative RNA Reprogramming Kit

2015年06月30日 PM10:00
このエントリーをはてなブックマークに追加


 

YOKOHAMA, Japan

We are pleased to announce that Stemgent Inc. (Cambridge, MA), a ReproCELL Group Company (Yokohama, Japan – JASDAQ: 4978) has launched its new Stemgent StemRNA™-SR Reprogramming Kit, the first commercially available RNA reprogramming kit applicable to cellular reprogramming of a blood-derived cell type. This non-viral, non-DNA reprogramming kit combines self-replicative RNA (srRNA) and microRNA technology, providing stem cell researchers with a safe, flexible and cost-effective cellular reprogramming method applicable to both human fibroblasts and blood-derived endothelial progenitor cells (EPCs). EPCs are uniquely genetically stable and can be efficiently established from fresh or cryopreserved human peripheral and cord blood. This latest innovation is being unveiled at the 13th Annual Meeting of the International Society for Stem Cell Research (ISSCR), June 24 – 27 in Stockholm, Sweden.

“The combination of readily-available patient blood samples with integration-free RNA reprogramming technology supported by the Stemgent StemRNA-SR Reprogramming Kit and protocol is a great step forward for researchers developing clinically relevant iPS cell lines” said Joseph Gentile (Chief Executive Officer, Stemgent).

About Stemgent (A ReproCELL Group Company)

Stemgent is engaged in working alongside some of the world’s leading stem cell scientists in developing innovative technology and application solutions for the advancement of stem cell research. Its mission is to help simplify and support cellular reprogramming research by producing products being designed by leading stem cell researchers worldwide. Stemgent stem cell reagents are available to customers worldwide.
For more information, visit: www.stemgent.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20150630005480/en/

CONTACT

Stemgent Inc.
Roseann Vardaro, +1-617-245-0043
Director of
Product Marketing
Roseann.Vardaro@stemgent.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc